Beta Blockers in COPD Management

Introduction to Beta Blocker Use

• The European Society of Cardiology recommends that beta-blockers are not contraindicated in COPD, including severe emphysema, though cardioselective beta-1 selective agents are strongly preferred 1
• The critical factor determining beta-blocker safety is bronchial hyperreactivity, not simply the presence of airflow obstruction, according to the European Heart Journal 1, 2

Key Considerations for Beta Blocker Use

• The American College of Cardiology states that beta-blockers remain relatively contraindicated in asthma, particularly in active or severe asthma 1, 3
• The European Society of Cardiology explicitly states that beta-blockers are only relatively contraindicated in asthma, but not in COPD, as per the 2016 ESC Heart Failure Guidelines 1

Selecting Appropriate Beta Blocker Agents

• The European Heart Journal recommends using only cardioselective beta-1 selective agents, such as bisoprolol 4, metoprolol succinate, or nebivolol 4

Initiation and Titration of Beta Blockers

• The European Heart Journal suggests starting with very low doses, such as bisoprolol 1.25 mg daily, metoprolol succinate 12.5-25 mg daily, or nebivolol 1.25 mg daily, and titrating every 1-2 weeks if well tolerated 4, 5
• Patients must be stable and euvolemic for at least 3 months before initiation, and not in acute COPD exacerbation 1

Monitoring and Management of Respiratory Symptoms

• The European Heart Journal recommends monitoring specifically for wheezing, increased dyspnea, lengthening of expiration phase, increased sputum production, or change in color 1
• If bronchospasm develops, increase inhaled beta-2 agonist therapy, temporarily reduce beta-blocker dose, or discontinue only if clearly necessary 1, 4

Absolute Contraindications

• Beta-blockers should be avoided in COPD patients with active asthma component, severe COPD with FEV1 <50% predicted, ≥20% reversibility in airway obstruction, acute COPD exacerbation, or severe bronchospasm 1, 3